In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans

Xenobiotica

Volumn 33, Issue 4, 2003, Pages 399-414

  Treiber, A ^a   Van Giersbergen, P L M ^a   Dingemanse, J ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; TEZOSENTAN;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; HUMAN; HUMAN EXPERIMENT; LIVER MICROSOME; MALE; NORMAL HUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; RECEPTOR AFFINITY; TISSUE DISTRIBUTION;

BIOTRANSFORMATION; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FECES; GLUCURONIDES; HEPATOCYTES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTEIN BINDING; PYRIDINES; RECEPTORS, ENDOTHELIN; SPECTROPHOTOMETRY, ULTRAVIOLET; TETRAZOLES;

EID: 0038143374     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825021000061624     Document Type: Article

References (27)

1. BROCKMOLLER, J., KIRCHHEINER, J., MEISEL, C. and ROOTS, I., 2000, Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics, 1, 125-151.
2. CHANG, J., CHADWYCK, R. W., ALLISON, J. C., HAYES, Y. O., TALLEY, D. L. and AUTRY, C. E., 1994, Microbial succession and intestinal enzyme activities in the developing rat. Journal of Applied Bacteriology, 77, 709-718.
3. CLOZEL, M., RAMUZ, H., CLOZEL, J.P., BREU, V., HESS, P., LÖFFLER, B. M., COASSOLO, P. and ROUX, S., 1999, Pharmacology of tezosentan, new endothelin receptor antagonist for parenteral use. Journal of Pharmacology and Experimental Therapeutics, 290, 840-846.
4. CRESPI, C. L. and STRESSER, D. M., 2000, Fluorimetric screening for metabolism-based drug-drug interactions. Journal of Pharmacology and Toxicology Methods, 44, 325-331.
5. DINGEMANSE, J., CLOZEL, M. and VAN GIERSBERGEN, P. L. M., 2002a, Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist. Journal of Cardiovascular Pharmacology, 39, 795-802.
6. DINGEMANSE, J., CLOZEL, M. and VAN GIERSBERGEN, P. L. M., 2002b, Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. British Journal of Clinical Pharmacology, 53, 355-362.
7. DOUMAS, B. T., BAYSE, D. D., CARTER, R. J., PETERS, T. and SCHAFFER, R., 1981, A candidate reference method for determination of total protein in serum. I. Development and validation. Clinical Chemistry, 27, 1642-1650.
8. FISHER, M. B., PAINE, M. F., STRELEVITZ, T. J. and WRIGHTON, S. A., 2001, The role of hepatic and extrahepatic UDP-glucuronyltransferases in human drug metabolism. Drug Metabolism Reviews, 33, 273-297.
9. GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker).
10. HOPFGARTNER, G., VETTER, W., MEISTER, W. and RAMUZ, H., 1996, Fragmentation of bosentan (Ro 470203) in ionspray mass spectrometry after collision-induced dissociation at low energy: a case of radical fragmentation of an even-electron ion. Journal of Mass Spectrometry, 31, 69-76.
11. JOHNSON, A. M., ROHLFS, E. M. and SILVERMAN, L. M., 2001, Proteins. In Tietz Fundamentals of Clinical Chemistry, 5th edn. C. A. Burtis and E. R. Ashwood (eds) (Philadelphia: W. B. Saunders), pp. 325-351.
12. KADDOURA, S. and POOLE-WILSON, P. A., 1996, Endothelin-1 in heart failure. A new therapeutic target? Lancet, 348, 418-419.
13. KRIETER, P. A., COLLETTI, A. E., MILLER, R. R. and STEARNS, R. A., 1995, Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. Journal of Pharmacology and Experimental Therapeutics, 273, 816-822.
14. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDAL, R. J., 1951, Protein measurement with Folin phenol reagents. Journal of Biological Chemistry, 193, 265-275.
15. LÜSCHER, T. F. and BARTON, M., 2000, Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 102, 2434-2440.
16. MILLER, V. P., STRESSER, D. M., BLANCHARD, A. P., TURNER, S. and CRESPI, C. L., 2000, Fluorimetric high-throughput screening for inhibitors of cytochrome P450. Annals of the New York Academy of Sciences, 919, 26-32.
17. PERRIER, L., BOURRIE, M., MARTI, E., TRONQUET, C., MASSE D., BERGER Y., MAGDALOU, J. and FABRE, G., 1994, In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. Journal of Pharmacology and Experimental Therapeutics, 271, 91-99.
18. RABELINK, T. J., KAASJAGER, K. A., STROES, E. S. and KOOMANS, H. A., 1996, Endothelin in renal pathophysiology: from experimental to therapeutic application. Kidney International, 50, 1827-1833.
19. REDMAN, A. R., 2001, Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy, 21, 235-242.
20. ROWLAND, M. and TOZER, T. N., 1995, Clinical Pharmacokinetics: Concepts and Applications, 3rd edn (Baltimore: Williams & Wilkins).
21. RUBIN, L. J., BADESCH, D. B., BARST, R. J., GALIÉ, N., BLACK, C. M., KEOGH, A., PULIDO, T., FROST, A., ROUX, S., LECONTE, I., LANDZBERG, M. and SIMONNEAU, G., 2002, Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine, 346, 896-903.
22. SEGLEN, P. O., 1973, Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Experimental Cell Research, 82, 391-398.
23. TONG, W., CHOWDHURY, S. K., CHEN, J. C., ZHONG, R., ALTON, K. B. and PATRICK, J. E., 2001, Fragmentation of N-oxides (deoxygenation) in atmospheric pressure ionization: investigation of the activation process. Rapid Communications in Mass Spectrometry, 15, 2085-2090.
24. VAN GIERSBERGEN, P. L. M., BODIN, F. and DINGEMANSE, J., 2002, Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. European Journal of Clinical Pharmacology, 58, 243-245.
25. VANE, F. M., BUGGE, C. J., RODRIGUEZ, L. C., ROSENBERGER, M. and DORAN, T. I., 1990, Human biliary metabolites of isotretinoin: identification, quantification, synthesis, and biological activity. Xenobiotica, 20, 193-207.
26. VON BAHR, C., GROTH, C. G., JANSSON, H., LUNDGREN, G., LIND, M. and GLAUMANN, H., 1980, Drug metabolism in human liver in vitro: establishment of a human liver bank. Clinical Pharmacology and Therapeutics, 27, 711-725.
27. WEBER, C., GASSER, R. and HOPFGARTNER, G., 1999, Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metabolism and Disposition, 27, 810-815.